Search
Trevi Therapeutics Inc
TRVIAdd to Watchlist
17.610USD
-1.040-5.58%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM
More Details of Trevi Therapeutics Inc Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Trevi Therapeutics Inc Info
Ticker SymbolTRVI
Company nameTrevi Therapeutics Inc
IPO dateMay 07, 2019
CEOGood (Jennifer L)
Number of employees26
Security typeOrdinary Share
Fiscal year-endMay 07
Address195 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06510
Phone12033042499
Websitehttps://www.trevitherapeutics.com/
Ticker SymbolTRVI
IPO dateMay 07, 2019
CEOGood (Jennifer L)
Company Executives of Trevi Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
81.55K
+5.71%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
81.55K
+5.71%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
FAQs
Who are the top five shareholders of Trevi Therapeutics Inc?
The top five shareholders of Trevi Therapeutics Inc are: Dr. David P. Meeker, M.D.
How many institutions hold shares of Trevi Therapeutics Inc (TRVI)?
As of 2026Q1, 339 institutions hold shares of Trevi Therapeutics Inc, with a combined market value of approximately 142.75M, accounting for 101.53% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5970560.00.